Cargando…
Combined integrated protocol/basket trial design for a first-in-human trial
BACKGROUND: Innovative trial designs are sought to streamline drug development in rare diseases. Basket- and integrated protocol designs are two of these new strategies and have been applied in a handful oncologic trials. We have taken the concept outside the realm of oncology and report about a fir...
Autores principales: | Derhaschnig, Ulla, Gilbert, Jim, Jäger, Ulrich, Böhmig, Georg, Stingl, Georg, Jilma, Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050564/ https://www.ncbi.nlm.nih.gov/pubmed/27716293 http://dx.doi.org/10.1186/s13023-016-0494-z |
Ejemplares similares
-
The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial
por: Kovacevic, Katarina D., et al.
Publicado: (2021) -
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing
por: Schoergenhofer, Christian, et al.
Publicado: (2018) -
Defibrotide enhances fibrinolysis in human endotoxemia – a randomized, double blind, crossover trial in healthy volunteers
por: Schoergenhofer, Christian, et al.
Publicado: (2019) -
The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020) -
Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers
por: Hobl, Eva-Luise, et al.
Publicado: (2015)